This is another measure taken by China Resources Sanjiu to broaden the product line of health care products since it formally established the Great Health Division at the beginning of this year. At present, Great Health Division has been listed as the three major development directions of China Resources together with OTC Division and Professional Brand Division.
The reporter of China Business News found that in recent years, many listed pharmaceutical companies tried to lay out a big health industry, but there were few explosions.
"Under the background of the current economic development in China, health care products have gradually developed into one of the categories with the strongest consumer willingness to pay." In a written interview with reporters, China Resources Sanjiu replied that "building differentiated products and upgrading brands" is one of the key strategic initiatives of China Resources Sanjiu in the next five years, with a view to building an upgraded self-diagnosis and treatment capacity system and striving to achieve the promotion from OTC to self-diagnosis and treatment leaders. "
It is expected to increase profits.
At the beginning of 20 17, China Resources Sanjiu formally established the Great Health Division. However, since 20 14, China Resources Sanjiu has been quietly extending to the big health industry and accumulating product reserves of the big health industry. Since the first "great health" product, 999 brown sugar ginger tea, was listed in China on 20 15, China Resources Sanjiu launched a variety of fast-moving products on 20 16, and the company said that new products will continue to be listed in the third quarter of this year.
For example, most pharmaceutical companies entering the big health industry, the layout of China Resources Sanjiu will still mainly rely on mergers and acquisitions. The acquisition of Shandong Shenghai is another shot of China Resources Sanjiu in the field of health care products since its strategic cooperation with Sanofi on 20 16. According to the announcement, Shandong Shenghai owns its own brands such as Ipsen and a variety of health care products, covering soft capsules, hard capsules, tablets, granules and other dosage forms.
It is worth noting that the net assets of Shandong Shenghai are 65.438+0.56 billion yuan, and the assessed value-added is 428 million yuan. The value-added rate of this transaction is as high as 27.3 1.3%. China Resources Sanjiu said that the high value-added rate is because the company has taken a fancy to the contributions of important intangible resources such as various business networks, service capabilities, talent teams and brand advantages in Shandong Shenghai.
"Shandong Shenghai has strong production capacity and supply chain management ability, which can meet the capacity demand of China Resources Sanjiu health care products after rapid growth and can be used as a healthy production base of China Resources Sanjiu; At the same time, relying on Shandong Shenghai's good health care product supply chain foundation, it will help the rapid growth of China Resources Sanjiu health business. " The company said.
"This acquisition will enable listed companies to quickly enter the mainstream health care products market and supplement the mainstream health care products and independent health care products brands in the market. On the other hand, listed companies, as domestic OTC leading enterprises, cover more than 300,000 pharmacies, and have obvious advantages in the terminal coverage and channel control of pharmacies, which has promoted the offline sales of Shandong Shenghai health care products from the terminal and channel of pharmacies.